Navigation Links
Researcher finds potential new use for old drugs
Date:11/12/2013

PULLMAN, Wash. A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found.

Researchers discovered that simple modifications to the drug furamidine have a major impact on its ability to affect specific human proteins involved in the on-off switches of certain genes.

"This was rather unexpected, given how relatively simple the molecules are that we modified and how difficult it has been to affect these proteins," said Gregory Poon, pharmaceutical scientist at Washington State University.

The proteins known as transcription factors regulate the expression of genes in a highly coordinated and intricate manner, making them attractive targets for therapeutic drugs. But it has proven difficult to design drugs to affect them, Poon said.

"For this reason, they have been called undruggable," he said. "Recently, however, scientists have been making headway in targeting these transcription factors with drugs, and now our results suggest this class of drugs can be a useful addition to the arsenal."

Furamidine belongs to a family of drugs known as heterocyclic dications. The drug has a long history of use in serious parasitic diseases such as malaria, African sleeping sickness and PCP, a common infection in HIV/AIDS.

"There is tremendous knowledge and experience with using furamidine and related drugs in humans, so these drugs have an important advantage over other classes of drugs that are relatively behind in clinical experience," Poon said.

Poon collaborated with researchers at Georgia State University. The team found that derivatives of furamidine can target a specific transcription factor known as PU.1.

PU.1 is a major factor in development and function of the human immune system, and it plays important roles in diseases such as some leukemias, multiple sclerosis and diabetes. PU.1 is also a member of a large family of related transcription factors, known as ETS, that is involved in a broader range of cancers and other diseases.

"I am fortunate to be working with some of the best people in this area," Poon said, referring to his collaborators, Dave Boykin and David Wilson of Georgia State University. "The challenge now is to fine-tune this class of drugs to make them as specific as possible to other ETS-family transcription factors as well."


'/>"/>

Contact: Gregory Poon
gpoon@wsu.edu
509-335-8341
Washington State University
Source:Eurekalert

Related biology news :

1. Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find
2. Wayne State researchers discover specific inhibitor for rheumatoid arthritis treatment
3. Protein illustrates muscle damage: McMaster researchers
4. NSF awards to UT Arlington researchers will fuel sustainable solutions
5. Researchers uncover origins of cattle farming in China
6. UT Southwestern researchers identify how body clock affects inflammation
7. Researchers suggest plan to address hypoxia in Gulf of Mexico
8. Researchers advocate for climate adaptation science
9. UMMS researchers answer century old question about 3D structure of mitotic chromosomes
10. NIH funds researchers using light to control and monitor neural activity
11. Researchers regrow hair, cartilage, bone, soft tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... July 16, 2020 , ... A study ... the Invictus Medical Neoasis™ active noise control device to attenuate typical noises in ... Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other bedside ...
(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:6/28/2020)... ... ... In an upcoming episode scheduled for the fall of 2020, Advancements with Ted ... local listings for more info. , Today, the majority of testing is performed at ... the country. Results are then available several days later. Now, in an effort to ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... 25, 2020 , ... Lumeda Inc. (“Lumeda”), a ... the company has entered a license agreement with Roswell Park Comprehensive Cancer Center ... rights to Roswell Park intellectual property surrounding a novel medical device and method ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... indoor environments, announced today that Derek Fournier has been appointed CEO and President. ... the Board, effective immediately. , “DeCurtis Corporation has been on an incredible ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, a biopharmaceutical company ... filed an Investigational New Drug application (IND) with the U.S. Food & Drug ... candidate NBTX-001 in patients with panic disorder (PD). , "Adding a PD trial ...
(Date:6/11/2020)... ... , ... PathSensors Inc., a Baltimore biotechnology company, announced today ... funded by the National Institute of Food and Agriculture (NIFA) entitled “Food Safety ... was to engineer and develop a field-deployable instrument for portable pathogen and toxin ...
Breaking Biology Technology: